Pharmaceutical care for a patient with rhino-orbito-cerebral mucormycosis

WU Xia; ZHAO Yinlong; ZHANG Zhiqing; DONG Weichong

doi:10.6039/j.issn.1001-0408.2024.12.21

您当前的位置：

首页 >

文章列表页 >

Pharmaceutical care for a patient with rhino-orbito-cerebral mucormycosis

更新时间：2024-06-25

- Pharmaceutical care for a patient with rhino-orbito-cerebral mucormycosis
- ZHONGGUO YAOFANG Vol. 35, Issue 12, Pages: 1533-1538(2024)
- 作者机构：
  
  1.河北医科大学第二医院药学部，石家庄　050051
  2.河北医科大学第二医院麻醉科ICU，石家庄　050051
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.12.21
  CLC： R969.3
- Published：30 June 2024，
  
  Received：29 December 2023，
  
  Revised：23 May 2024，
扫描看全文
吴瑕,赵银龙,张志清等.1例鼻-眶-脑型毛霉菌病患者的药学监护 ^Δ[J].中国药房,2024,35(12):1533-1538.

WU Xia,ZHAO Yinlong,ZHANG Zhiqing,et al.Pharmaceutical care for a patient with rhino-orbito-cerebral mucormycosis[J].ZHONGGUO YAOFANG,2024,35(12):1533-1538.
吴瑕,赵银龙,张志清等.1例鼻-眶-脑型毛霉菌病患者的药学监护 ^Δ[J].中国药房,2024,35(12):1533-1538. DOI： 10.6039/j.issn.1001-0408.2024.12.21.

WU Xia,ZHAO Yinlong,ZHANG Zhiqing,et al.Pharmaceutical care for a patient with rhino-orbito-cerebral mucormycosis[J].ZHONGGUO YAOFANG,2024,35(12):1533-1538. DOI： 10.6039/j.issn.1001-0408.2024.12.21.

摘要

目的

为鼻-眶-脑型毛霉菌病（ROCM）的临床诊疗和药学监护提供思路。

方法

临床药师参与1例ROCM患者的诊断和治疗过程，结合相关治疗指南及药物可及性、经济性等实际情况，协助医生制定两性霉素B胆固醇硫酸酯复合物联合泊沙康唑的抗真菌治疗方案，并监测临床疗效、肝肾功能及电解质变化。根据外周血和脑脊液检查结果，临床药师建议给予两性霉素B脱氧胆酸盐鞘内注射、滴鼻、滴眼以提高感染灶局部药物浓度，并协助医生确定给药剂量及药液配制方法；针对泊沙康唑血药谷浓度不达标的问题，临床药师建议将泊沙康唑口服混悬液更换为泊沙康唑肠溶片，并对患者进行治疗药物监测（TDM）、个体化用药指导及出院长期随访。

结果

医生采纳了临床药师的建议。患者经治疗后，病情好转，准予带药出院。

结论

临床药师通过调整药物剂量和剂型、开展用药监护和TDM等药学服务手段，为ROCM患者制定个体化治疗方案，有助于保障患者用药的安全性。

Abstract

OBJECTIVE

To provide ideas for clinical diagnosis， treatment and pharmaceutical care of rhino-orbito-cerebral mucormycosis （ROCM）.

METHODS

The diagnosis and treatment of 1 case of ROCM in which clinical pharmacists participated were analyzed. Combined with treatment guidelines， the actual situation of drug accessibility and economy， clinical pharmacists recommend amphotericin B colloidal dispersion in combination with posaconazole to treat fungal infections. The clinical efficacy， liver and kidney function and electrolytes were monitored. To increase the local concentration of amphotericin B deoxycholate （AmB-D）， clinical pharmacists assisted physicians in determining the dosage and formulation of AmB-D for intrathecal injection， intranasal and eye drops based on the results of blood and cerebrospinal fluid examinations. In response to the situation that the plasma trough concentration of posaconazole had not reached the target， clinical pharmacists recommended that Posaconazole oral suspension was replaced with Posaconazole enteric-coated tablets， and provided the patient with therapeutic drug monitoring （TDM）， individualized medication guidance， and long-term follow-up after discharge.

RESULTS

The clinician adopted the advice of the clinical pharmacists. After treatment， the patient was discharged from the hospital with medicine after her condition improved.

CONCLUSIONS

Clinical pharmacists develop individualized treatment protocols for ROCM patients by adjusting dose and dosage forms， providing medication monitoring and TDM to ensure the safety of drug use for patients.

关键词

鼻-眶-脑型毛霉菌病两性霉素B胆固醇硫酸酯复合物泊沙康唑治疗药物监测临床药师

Keywords

amphotericin B colloidal dispersionposaconazoletherapeutic drug monitoringclinical pharmacist

references

许蕊，陈芳艳，赵静雅，等. 毛霉菌病预防与控制研究进展[J]. 中华医院感染学杂志，2023，33（13）：2075-2080.

XU R，CHEN F Y，ZHAO J Y，et al. Progress of research on prevention and control of mucormycosis[J]. Chin J Nosocomiology，2023，33（13）：2075-2080.

CORNELY O A，ALASTRUEY-IZQUIERDO A，ARENZ D，et al. Global guideline for the diagnosis and management of mucormycosis：an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium[J]. Lancet Infect Dis，2019，19（12）：e405-e421.

TISSOT F，AGRAWAL S，PAGANO L，et al. ECIL-6 guidelines for the treatment of invasive candidiasis，aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients[J]. Haematologica，2017，102（3）：433-444.

WEI L W，ZHU P Q，CHEN X Q，et al. Mucormycosis in Mainland China：a systematic review of case reports[J]. Mycopathologia，2022，187（1）：1-14.

艾雄飞，陈少文，林翀. 肾移植术后并发毛霉菌感染2例临床分析[J]. 中国热带医学，2023，23（10）：1122-1126.

AI X F，CHEN S W，LIN C. Diagnostic value and analysis of two cases with Mucor infection after renal transplan-tation[J]. China Trop Med，2023，23（10）：1122-1126.

蒋群芳，王亮良，徐杰，等. 肾移植术后移植肾毛霉菌感染治疗2例[J]. 中国医院药学杂志，2023，43（21）：2462-2466.

JIANG Q F，WANG L L，XU J，et al. Treatment of renal graft Mucor infection in two cases after renal transplantation[J]. Chin J Hosp Pharm，2023，43（21）：2462-2466.

张远，杨明华. 白血病继发毛霉菌病和曲霉菌病混合感染1例并文献复习[J]. 中南大学学报（医学版），2023，48（7）：1105-1112.

ZHANG Y，YANG M H. Leukemia followed by mixed infection with mucormycosis and aspergillosis：a case report and literature review[J]. J Cent South Univ （Med Sci），2023，48（7）：1105-1112.

ZHAO Y L，TIAN W B，YANG J K，et al. Fungal endophthalmitis in a case of rhino-orbito-cerebral mucormy-cosis：successfully treated with amphotericin B colloidal dispersion[J]. Front Microbiol，2022，13：910419.

沈敏，杨鑫，黄梅. 糖尿病合并鼻眶脑型毛霉菌病1例诊治体会[J]. 内科急危重症杂志，2019，25（4）：345-347，352.

SHEN M，YANG X，HUANG M. Diagnosis and treatment of diabetes mellitus complicated with nasoorbital mucormycosis：a case report[J]. J Crit Care Intern Med，2019，25（4）：345-347，352.

李博志，曹雅，曹秉振. 鼻-眼-脑型真菌感染诊治[J]. 中国真菌学杂志，2015，10（6）：380-384.

LI B Z，CAO Y，CAO B Z. Diagnosis and treatment of nasal-eye-brain fungal infection[J]. Chin J Mycol，2015，10（6）：380-384.

LIU Y C，ZHANG J，HAN B，et al. Case report：diagno-stic value of metagenomics next generation sequencing in intracranial infection caused by Mucor[J]. Front Med，2021，8：682758.

中国医药教育协会真菌病专业委员会，中国毛霉病专家共识工作组. 中国毛霉病临床诊疗专家共识：2022[J]. 中华内科杂志，2023，62（6）：597-605.

Medical Mycology Society of Chinese Medicine and Education Association，Chinese Mucormycosis Expert Consensus Group.Expert consensus on diagnosis and management of mucormycosis in China[J]. Chin J Intern Med，2023，62（6）：597-605.

李飒，梅隆，张曦，等.不同两性霉素B脂质制剂说明书的异同点分析[J].临床药物治疗杂志，2023，21（11）：25-28.

LI S，MEI L，ZHANG X，et al. Analysis of similarities and differences in the package insert of different amphotericin B lipid complex[J].Clin Med J，2023，21（11）：25-28.

赵东陆，马军，黄晓军，等. 注射用两性霉素B胆固醇硫酸酯复合物用药指导原则[J]. 临床血液学杂志，2022，35（5）：303-308.

ZHAO D L，MA J，HUANG X J，et al. Guiding principle for the administration of amphotericin B colloidal dispersion for injection[J]. J Clin Hematol，2022，35（5）：303-308.

GUO L S. Amphotericin B colloidal dispersion：an improved antifungal therapy[J]. Adv Drug Deliv Rev，2001，47（2/3）：149-163.

HAMILL R J. Amphotericin B formulations：a comparative review of efficacy and toxicity[J]. Drugs，2013，73（9）：919-934.

LIU J T，MA X X. Amphotericin B colloidal dispersion：an effective drug for the treatment of mucormycosis in China[J]. Front Cell Infect Microbiol，2023，13：1147624.

两性霉素B脱氧胆酸盐临床合理应用专家共识编写组，中国医药教育协会感染疾病专业委员会，中华医学会细菌感染与耐药防控专业委员会. 两性霉素B脱氧胆酸盐临床合理应用专家共识：2022[J]. 中华医学杂志，2023，103（16）：1173-1183.

Expert Panel for Clinical Rational Application of Amphotericin B Deoxycholate，Infectious Diseases Society of China，Chinese Society of Bacterial Infection and Resistance. Expert consensus on rational clinical application of amphotericin B deoxycholate：2022[J]. Natl Med J China，2023，103（16）：1173-1183.

吴喜福，张革化，赵耕，等. 两性霉素B鼻内应用改善慢性鼻-鼻窦炎预后的Meta分析[J]. 中国耳鼻咽喉头颈外科，2014，21（4）：169-173.

WU X F，ZHANG G H，ZHAO G，et al. Meta analysis of topical amphotericin B for the treatment of chronic rhinosinusitis[J]. Chin Arch Otolaryngol Head Neck Surg，2014，21（4）：169-173.

陈海婷，冯雪艳，范玉香. 角膜基质内注射两性霉素B治疗真菌性角膜炎[J]. 中国眼耳鼻喉科杂志，2015，15（5）：344-347.

CHEN H T，FENG X Y，FAN Y X. Intrastromal amphotericin B injection in the treatment of fungal keratitis[J]. Chin J Ophthalmol Otorhinolaryngol，2015，15（5）：344-347.

陈璐，王陶陶，董亚琳.泊沙康唑药动学-药效学及其治疗药物监测研究进展[J]. 药学进展，2015，39（11）：810-816.

CHEN L，WANG T T，DONG Y L.Advances in research on pharmacokinetics/pharmacodynamics of posaconazole and its therapeutic drug monitoring[J]. Prog Pharm Sci，2015，39（11）：810-816.

DOLTON M J，BRÜGGEMANN R J，BURGER D M，et al. Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis[J]. Antimicrob Agents Chemother，2014，58（11）：6879-6885.

DEKKERS B G J，BAKKER M，VAN DER ELST K C M，et al. Therapeutic drug monitoring of posaconazole：an update[J]. Curr Fungal Infect Rep，2016，10：51-61.

KRISHNA G，MA L，MARTINHO M，et al. Single-dose phase Ⅰ study to evaluate the pharmacokinetics of posa-conazole in new tablet and capsule formulations relative to oral suspension[J]. Antimicrob Agents Chemother，2012，56（8）：4196-4201.

张飞雨，张瑞霞，宋学武，等. 影响泊沙康唑血药浓度相关因素的研究进展[J]. 中国医院药学杂志，2021，41（9）：971-976.

ZHANG F Y，ZHANG R X，SONG X W，et al. Research progress of influencing factors for plasma concentration of posaconazole[J]. Chin J Hosp Pharm，2021，41（9）：971-976.

泊沙康唑临床应用专家组. 泊沙康唑临床应用专家共识[J]. 国际呼吸杂志，2020，40（4）：241-261.

Working Group of Expert Consensuson Clinical Use of Posaconazole.Expert consensus on clinical use of posa-conazole[J]. Int J Respir，2020，40（4）：241-261.

MÄRTSON A G，VERINGA A，VAN DEN HEUVEL E R，et al. Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations[J]. Mycoses，2019，62（8）：698-705.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Pharmaceutical care of reactivating anthracycline chemotherapy in a patient with advanced breast cancer combined with thyroid cancer

Rational use management standards of national key monitoring drug

Application practice of drug clinical comprehensive evaluation thinking in management of temporary drug purchase in hospital

Pharmaceutical care for a case of infective endocarditis caused by Micrococcus luteus complicated with severe pneumonia

Related Author

ZHANG Guangquan

LU Qi

YAN Dan

XU Silu

XU Feifei

BIAN Yuan

HAN Yong

YAN Junfeng

Related Institution

Dept. of Pharmaceutical Administration， Changzhou Cancer Hospital

Dept. of Pharmacy， Jiangsu Cancer Hospital/Jiangsu Institute of Cancer Research/the Affiliated Cancer Hospital of Nanjing Medical University

Dept. of Pharmacy， Xuzhou Cancer Hospital

Dept. of Pharmacy， Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital

Personalized Drug Therapy Key Laboratory of Sichuan Province， School of Medicine， University of Electronic Science and Technology of China

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰